<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136213">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01963780</url>
  </required_header>
  <id_info>
    <org_study_id>OCS-LUN-012013</org_study_id>
    <nct_id>NCT01963780</nct_id>
  </id_info>
  <brief_title>International EXPAND Lung Pivotal Trial</brief_title>
  <acronym>EXPANDLung</acronym>
  <official_title>International Trial to Evaluate the Safety and Effectiveness of The Portable Organ Care System (OCS™) Lung For Recruiting, Preserving and Assessing Expanded Criteria Donor Lungs for Transplantation (EXPAND Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TransMedics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TransMedics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and effectiveness of the OCS™ Lung to recruit, preserve and assess
      donor lungs that may not meet current standard donor lung acceptance criteria for
      transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The OCS™ Lung is to be used to recruit, preserve and assess donor lungs that may not meet
      current standard donor lung acceptance criteria from one or more of the following
      characteristics:

        -  Donor PaO2/FiO2 ≤ 300 mmHg; or

        -  Expected ischemic time &gt; 6 hours; or

        -  Donor after Cardiac Death (DCD donor); or

        -  Donor age ≥55 years old
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>COMPOSITE endpoint of patient survival at Day-30 post transplant and absence of Primary Graft Dysfunction (PGD) Grade 3 during the first 72 hours post lung transplant</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The COMPOSITE incidence of patient survival at day-30 post transplant and freedom of Primary Graft Dysfunction Grade 3 during the first 72 hours after lung transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of ISHLT primary graft dysfunction (PGD) Grade 2 or 3 at T72 hours post lung transplantation</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Primary Graft Dysfunction Grade 3 at T72 hours</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of Lung Graft Related Serious Adverse Events during the first 30 days post lung transplantation</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Lung Transplant</condition>
  <arm_group>
    <arm_group_label>OCS Lung Tx.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OCS Lung Preservation</intervention_name>
    <arm_group_label>OCS Lung Tx.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least one of the following:

               -  Donor PaO2/FiO2 ≤ 300 mmHg; or

               -  Expected ischemic time &gt; 6 hours; or

               -  Donor after Cardiac Death (DCD donor); or

               -  Donor age ≥55 years old

        Exclusion Criteria:

          -  • Presence of moderate to severe traumatic lung injury with air and/or blood leak

               -  Presence of confirmed active pneumonia or persistent purulent secretions on
                  repeated bronchoscopy evaluation or ET suction

               -  Previous history of pulmonary disease

               -  Multiple transfusions of &gt;10 pRBCs units

               -  ABO incompatibility

               -  Tobacco history of &gt;20 packs per year
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abbas Ardehali, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dirk Van Raemdonck, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Leuven Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Waleed H Hassanein, MD</last_name>
    <phone>978-552-0901</phone>
    <email>whassanein@transmedics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tamer I Khayal, MD</last_name>
    <phone>978-552-0901</phone>
    <email>tkhayal@transmedics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Joseph's Hospital and Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael A Smith, MD</last_name>
      <phone>602-406-4000</phone>
      <email>Michael.Smith011@DignityHealth.org</email>
    </contact>
    <investigator>
      <last_name>Michael A Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California at Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Abbas Ardehali, MD</last_name>
      <phone>310-825-5841</phone>
      <email>AArdehali@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Abbas Ardehali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jasleen Kukreja, MD</last_name>
      <phone>415-353-4145</phone>
      <email>Jasleen.Kukreja@ucsfmedctr.org</email>
    </contact>
    <investigator>
      <last_name>Jasleen Kukreja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel Loor, MD</last_name>
      <phone>612-625-4941</phone>
      <email>gloor@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Gabriel Loor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Leuven Hospital</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dirk Van Raemdonck, MD, PhD</last_name>
      <phone>3216346823</phone>
      <email>dirk.vanraemdonck@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Drik Van Raemdonck, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>D-300625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregor Warnecke, MD</last_name>
      <phone>011495115326590</phone>
      <email>warnecke.gregor@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Gregor Warnecke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Belgium</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 9, 2014</lastchanged_date>
  <firstreceived_date>September 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung transplantation</keyword>
  <keyword>lung preservation</keyword>
  <keyword>breathing lung transplant</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
